Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock Price Target Lowered at Barclays

Ultragenyx Pharmaceutical (NASDAQ:RARE) had its target price cut by Barclays from $35.00 to $32.00 in a research note published on Thursday,Benzinga reports. They currently have an overweight rating on the biopharmaceutical company’s stock.

A number of other research analysts have also weighed in on RARE. William Blair raised Ultragenyx Pharmaceutical to a “hold” rating in a report on Wednesday, September 23rd. Cantor Fitzgerald raised their target price on Ultragenyx Pharmaceutical from $33.00 to $39.00 and gave the stock an “overweight” rating in a report on Friday, September 18th. Jefferies Financial Group dropped their price objective on shares of Ultragenyx Pharmaceutical from $77.00 to $28.00 and set a “buy” rating on the stock in a research note on Thursday, September 3rd. JPMorgan Chase & Co. cut shares of Ultragenyx Pharmaceutical from an “overweight” rating to a “neutral” rating and decreased their target price for the company from $80.00 to $36.00 in a research note on Thursday, September 3rd. Finally, Wells Fargo & Company increased their price target on shares of Ultragenyx Pharmaceutical from $18.00 to $19.00 and gave the stock an “equal weight” rating in a report on Wednesday. One research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, eleven have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Ultragenyx Pharmaceutical currently has an average rating of “Hold” and a consensus target price of $29.79.

Ultragenyx Pharmaceutical Price Performance

Ultragenyx Pharmaceutical stock opened at $15.57 on Thursday. Ultragenyx Pharmaceutical has a 1-year low of $12.73 and a 1-year high of $39.89. The business has a fifty day moving average price of $16.24 and a 200-day moving average price of $22.75.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last posted its quarterly earnings data on Tuesday, November 3rd. The biopharmaceutical company reported ($1.16) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.10) by ($0.06). The firm had revenue of $173.00 million for the quarter, compared to analysts’ expectations of $182.49 million. The firm’s quarterly revenue was up 8.2% on a year-over-year basis. During the same quarter in the prior year, the business posted ($1.81) EPS. Research analysts anticipate that Ultragenyx Pharmaceutical will post -4.30 EPS for the current fiscal year.

Insider Activity at Ultragenyx Pharmaceutical

In other news, CFO Howard Horn sold 7,066 shares of the firm’s stock in a transaction that occurred on Thursday, October 15th. The stock was sold at an average price of $15.27, for a total value of $107,897.82. Following the transaction, the chief financial officer owned 89,229 shares in the company, valued at $1,362,526.83. This trade represents a 7.34% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 8,510 shares of company stock worth $127,561 over the last ninety days. 5.20% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Ultragenyx Pharmaceutical

Hedge funds and other institutional investors have recently modified their holdings of the business. Assenagon Asset Management S.A. raised its position in Ultragenyx Pharmaceutical by 295.4% in the third quarter. Assenagon Asset Management S.A. now owns 477,869 shares of the biopharmaceutical company’s stock valued at $7,182,000 after purchasing an additional 357,005 shares during the period. BlackRock Inc. acquired a new position in Ultragenyx Pharmaceutical in the 2nd quarter valued at about $355,746,000. Connor Clark & Lunn Investment Management Ltd. acquired a new position in Ultragenyx Pharmaceutical in the 2nd quarter valued at about $6,397,000. Deutsche Bank AG purchased a new stake in Ultragenyx Pharmaceutical during the second quarter worth about $5,503,000. Finally, Corient Private Wealth LP purchased a new position in shares of Ultragenyx Pharmaceutical in the second quarter valued at approximately $4,644,000. 97.67% of the stock is owned by hedge funds and other institutional investors.

Trending Headlines about Ultragenyx Pharmaceutical

Here are the key news stories impacting Ultragenyx Pharmaceutical this week:

• Positive Sentiment: Some analysts raised targets: TD Cowen lifted its target to $19 and Morgan Stanley to $22; both maintained their existing ratings. TD Cowen analyst recommendations
• Neutral Sentiment: Ultragenyx reaffirmed its 2026 and 2027 earnings guidance, offering some continuity, though this did not offset the weaker quarterly results and lower analyst targets. Guidance update
• Negative Sentiment: Q3 revenue of $173 million and adjusted EPS of negative $1.16 fell short of analyst expectations of $182.5 million and negative $1.10, respectively. Revenue nevertheless grew 8.2% year over year. Q3 results
• Negative Sentiment: Citigroup cut its target from $32 to $22 and Barclays from $35 to $32, despite retaining Buy and Overweight ratings. Canaccord also lowered its target from $39 to $34. These reductions signal more cautious expectations even though the targets remain above the current share price. Citigroup analyst recommendations
• Negative Sentiment: Goldman Sachs and Wedbush also cut targets, to $17 and $22, respectively, maintaining Neutral ratings. A Seeking Alpha analysis highlighted dependence on CRYSVITA, limited contribution from newer launches, and profitability plans reliant on R&D cuts—factors that may weigh on confidence in longer-term growth. Ultragenyx analysis

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing treatments for rare and ultra-rare diseases. The company concentrates on conditions with significant unmet medical needs, including genetic, metabolic and endocrine disorders, and uses biologics, small molecules and gene therapy approaches in its research and development programs.

Ultragenyx’s commercial portfolio includes Crysvita (burosumab), a treatment for X-linked hypophosphatemia and related disorders; Mepsevii (vestronidase alfa), an enzyme replacement therapy for mucopolysaccharidosis VII; and Dojolvi (triheptanoin), a therapy for long-chain fatty acid oxidation disorders.